CVS Health Board Change: Director Resigns; Teresa Heitsenrether Appointed

What Happened

• CVS Health filed an 8-K (Aug 17, 2026) reporting that director Larry M. Robbins resigned from the Board effective August 13, 2026. The resignation was not due to any disagreement with the company.
• The Board appointed Teresa Heitsenrether to join the Board, effective November 18, 2026. Ms. Heitsenrether (age 61) is Executive Vice President and Chief Data & Analytics Officer of JPMorgan Chase and is a member of its Operating Committee.

Key Details

• Larry M. Robbins’ resignation effective date: August 13, 2026.
• New director effective date: November 18, 2026.
• Teresa Heitsenrether background: EVP & Chief Data & Analytics Officer, former CEO of Securities Services and Global Head of Prime Brokerage & Equity Financing at JPMorgan Chase; holds an MBA (NYU) and B.S. in Finance (Fordham).
• Board determination: Ms. Heitsenrether was deemed an “independent” director under NYSE rules and CVS’s Corporate Governance Guidelines; her non-employee director pay will match other non-employee directors and be prorated for her start date.
• Disclosure: A press release announcing the resignation and appointment was furnished as Exhibit 99.1 to the 8-K (filed Aug 17, 2026). No reportable related-party transactions with Ms. Heitsenrether since the start of the last fiscal year.

Why It Matters

• Board composition and independence can affect corporate oversight and strategy. Investors should note CVS added a director with senior data and analytics experience, which may be relevant as the company continues to leverage data capabilities across its businesses.
• The filing indicates the change was routine (not due to disagreement) and no immediate financial terms or conflicts were disclosed, so there is no direct financial impact reported in this 8-K.